GHRP-2

GHRP-2 (growth hormone–releasing peptide-2) is a synthetic peptide in the growth hormone secretagogue family. It was one of the earlier agents explored for stimulating endogenous GH release via non-physiologic receptor activation.

Over time, interest has shifted toward newer, more selective molecules, but GHRP-2 still appears in experimental and legacy wellness discussions. Its regulatory status and product quality controls vary substantially between jurisdictions and suppliers.

GHRP-2 is designed to bind the growth hormone secretagogue receptor (GHSR), mimicking certain actions of ghrelin-like signaling. At a high level, activation of this pathway can:

• Increase pulsatile growth hormone release from the pituitary
• Influence appetite and energy balance through central mechanisms
• Interact with other endocrine axes in ways that are still being clarified

Compared with later secretagogues, GHRP-2 has been associated in some reports with broader off-target endocrine effects, which has informed evolving views on its risk–benefit profile.

In most contemporary medical practice, GHRP-2 is not a frontline or approved therapy for growth hormone–related conditions. It is more often referenced in historical research, exploratory protocols, or unregulated wellness contexts that sit outside formal guidelines.

Any proposed use should be evaluated against local laws, ethical standards, and the availability of better-characterized options. Decisions about whether and how to treat GH-axis issues belong with clinicians who can weigh the evolving evidence and alternatives.

GHRP-2 is not caught by a catch-all clause; it is written into the WADA Prohibited List as a named example under S2.2.4, "Growth hormone releasing factors," in the GHRP sub-bullet alongside alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-3, GHRP-4, GHRP-5 and GHRP-6. As a non-Specified Substance in S2, the default sanction for a first violation is four years.

The prohibition is analytically enforceable. In a controlled administration study in volunteers, GHRP-2 and its free-acid metabolites were recovered from urine and remained detectable up to 47 hours after a single nasal dose — the longest window among the five GH-releasing peptides tested (Semenistaya et al., Drug Test Anal 2015). Because routine sports-drug-testing methods screen for those metabolites, a subcutaneous dose taken two days before an out-of-competition visit is not a safe distance.

Two sanctions in North American professional leagues show how the substance actually surfaces:

• Jodie Meeks (NBA, 25 games). The Washington Wizards guard was suspended on 13 April 2018 under the NBA/NBPA anti-drug program after testing positive for ipamorelin and GHRP-2. The timing cost him the playoffs, and he contested the finding (ESPN, 13 April 2018).

• Steven Wright (MLB, 80 games). The Boston Red Sox pitcher was suspended on 6 March 2019 for GHRP-2 under MLB's Joint Drug Prevention and Treatment Program, after an off-season test and a failed appeal. He did not dispute the test result: "We couldn't figure out how this substance got into my body. But at the end of the day, it's my responsibility" (ESPN, 6 March 2019).

Both cases involved out-of-competition or off-season samples, which is the point: an S2 substance is prohibited year-round, and the testing pool does not close in the off-season.

Described effects have included flushing, increased appetite, transient increases in prolactin or cortisol in some settings, local injection-site reactions, and nonspecific symptoms such as headache or fatigue.

As with other GH-axis interventions, theoretical concerns extend to long-term effects on glucose metabolism, soft-tissue growth, or tumor biology, especially in individuals with underlying risk factors. These considerations are best handled in a clinical risk–benefit framework rather than informal experimentation.

GHRP-2 (Pralmorelin) is a potent GH secretagogue with a short half-life, necessitating frequent administration to mimic natural pulsatility.

This information summarizes commonly discussed research practices. GHRP-2 stimulates hunger less than GHRP-6 but more than Ipamorelin.

GHRP-2 usually appears as a lyophilized powder for reconstitution. It also exists as a licensed pharmaceutical: in Japan it is marketed under the generic name pralmorelin (developed as KP-102) and administered intravenously as a growth hormone stimulation test, with a peak GH below 9 µg/L defining severe adult GH deficiency (Fukuda et al., Neurol Med Chir 2014). That is a different product, route and purpose from a research-grade vial.

In non-clinical use it is most often combined with a GHRH analog such as modified GRF 1-29 or sermorelin. That pairing has a real experimental basis: 24-hour subcutaneous co-infusion of GHRP-2 with GHRH drove more GH secretion than either agonist alone in healthy older adults, and acute two-peptide synergy was about three-fold greater in young than older volunteers and 2.3-fold higher in elderly women than men (Bowers et al., J Clin Endocrinol Metab 2004). The specific milligram combinations sold as blends have not themselves been studied.

Early research on GHRP-2 examined its ability to stimulate GH release, sometimes in comparison with other secretagogues and GHRH analogs. Outcomes of interest included GH and IGF-1 levels, body composition changes, and short-term tolerability.

Over time, attention has shifted toward different classes of therapies for most clinical questions, and the evidence base for GHRP-2 remains relatively specialized. Readers interested in detailed data should consult primary studies and consider how older findings map onto current practice.

For deeper dives on this peptide, see:

• GHRP-2 benefits and areas of interest
• GHRP-2 side effects and safety context
• GHRP-2 dosing concepts (educational)
• GHRP-2 research and evidence overview

Is GHRP-2 approved anywhere? Yes, but only as a diagnostic agent. In Japan the GHRP-2 (pralmorelin) stimulation test is available and recommended as a convenient, safe alternative to the insulin tolerance test for diagnosing growth hormone deficiency, with a cut-off peak GH of 9 µg/L for severe adult GHD (Fukuda et al., Neurol Med Chir 2014). It has no approved therapeutic indication anywhere.

Does GHRP-2 make you hungry? Measurably. Seven lean healthy men given a subcutaneous GHRP-2 infusion at 1 µg/kg/h for 270 minutes ate 35.9 ± 10.9% more at a subsequent buffet meal than on saline — 32.5 versus 24.2 kcal/kg, p = 0.008 — with no change in which macronutrients they chose (Laferrère et al., J Clin Endocrinol Metab 2005). It is a ghrelin mimetic, and this is ghrelin's other job.

Does it stop working over time? Partially. Over 30 days of continuous subcutaneous delivery in 17 healthy older adults, GH secretion was stimulated more than three-fold on day 1 but only about 1.8-fold by days 14 and 30 — while IGF-1 held a stable plateau throughout and safety screening tests remained normal (Bowers et al., J Clin Endocrinol Metab 2004). Class reviews describe this partial desensitisation as more pronounced during continuous infusion and less during intermittent dosing (Ghigo et al., Eur J Endocrinol 1997).

Does GHRP-2 raise cortisol? Enough that clinicians use it to test the adrenal axis. A 100 µg intravenous dose in 15 patients investigated for hypopituitarism produced a median peak cortisol of 21.4 µg/dL in those with normal adrenal function versus 11.4 in those with confirmed HPA-axis failure, correlating with the insulin tolerance test at r = 0.817 (Kano et al., Peptides 2010). This is the concrete meaning of GHRP-2 being "less selective" than ipamorelin.

GHRP-2 vs GHRP-6 — which is better studied? GHRP-2, clearly. GHRP-6 is the original hexapeptide and the one that opened the field, but GHRP-2 has the diagnostic validation, the 30-day dosing study and the measured appetite data.

Is it detectable in doping tests? Yes. GHRP-2 is prohibited at all times under WADA section S2, and GHRP-2, its free acid and its (1-3) free acid metabolite have been detected in urine up to 47 hours after administration (Semenistaya et al., Drug Test Anal 2015).